Gri Bio Q2 FY26 net loss narrows to $1.64 million; R&D expenses drop 78.34% to $407,000
GRI•Cash position and runway
Cash totaled $10.9 million at June 30, 2026; cash runway is projected through Q2 2027 under the current operating plan.
Q2 FY26 loss narrows as expenses decline
Gri Bio posted a GAAP net loss of $1.64 million for the quarter ended June 30, 2026, narrowing from $2.89 million.
Operating loss narrowed to $1.65 million from $2.9 million as operating expenses fell to $1.65 million from $2.9 million.
R&D spending falls after Phase 2a trial completion
R&D spending dropped to $407,000 from $1.88 million due to completion of the Phase 2a GRI-0621 trial.
G&A costs rose to $1.24 million from $1.02 million on higher public company expenses.
